Cruz FJM

Language: Spanish
References: 15
Page: 190-193
PDF size: 62.08 Kb.

ABSTRACT

When first symptoms of ischemic cardiopathy come up, it is time for a “clear beginning”, and for secondary prevention. Although pharmacological and non-pharmacological resources are available, its clinical application isn’t as good as it can be. Secondary prevention is supported by changes in the lifestyle (quit smoking, balanced nutrition and regular workout), along with controlling risk factors and rational employ of therapeutic measures, will be of great help. Otherwise stated, patients should take aspirin, a statin, beta-blockers and angiotensin-converting enzyme inhibitors. If secondary prevention is in order, lets do it.

REFERENCES

1. Velasco JA, Cosín J, Lopez-Sendón JL, De Teresa E, De Oya M, Sellers G: Nuevos datos sobre la prevención secundaria del infarto de miocardio en España. Resultados del estudio Prevese II. Rev Esp Cardiol 2002; 55: 801-809.

2. EUROASPIRE I and II Group: Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.

3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifcova R, Dallongeville J: European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-1610.

4. Serrano M, Madoz E, Ezpeleta I, San Julián B, Amezqueta C, Perez Marco JA: Abandono del tabaco y riesgo de nuevo infarto en pacientes coronarios: estudio de casos y controles anidados. Rev Esp Cardiol 2003; 56: 445-451.

5. Collins R, Armitage J, Parish S, Sleigh P, Peto R: Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003; 361: 2005-2016.

6. Nissen S: REVERSAL Study. Presentado en Hot Line Sessions en el American Heart Association Scientific Sessions. Orlando 2003.

7. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290(17): 2292-300.

8. Bertomeu V: Guías sobre el tratamiento de la hipertensión arterial 2003: ¿aclaran o confunden? Rev Esp Cardiol 2003; 56: 940-943.

9. Cruz-Fernández JM, Lopez Bescos L, García-Dorado D, Lopez G-Aranda V, Cabadés A, Martín Jadraque L: Randomized comparative trial of triflusaland aspirin following acute myocardial infarction. Eur Heart J 2000; 21: 457-465.

10. Matías-Guiú J, Ferro JM, Alvarez-Sabín J, Torres F, Jimenez MD, Lago A: Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: The TACIP study: A randomized, double blind, multicenter trial. Stroke 2003; 34: 840-848.

11. Cruz-Fernández JM: Evidencias clínicas con Clopidogrel en cardiología. Rev Esp Cardiol Supl 2003; 3: 1A-22A.

12. Olson SB: Excutive Steering Committee on. behalf of the SPORTIF III investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003; 362: 1691-1698.

13. León de la Fuente R, Gurfinkel EP, Toledo D, Mautner B, por el grupo de Estudio FLUVACS: Vacunación antigripal en pacientes con Síndromes Coronarios Agudos: Beneficio del tratamiento en diferentes subgrupos. Rev Esp Cardiol 2003; 56: 949-954.

14. Pislaru SV, Van de Werf F: Antibiotic therapy for coronary artery disease. Can WIZARD change it all? JAMA 2003; 290: 1515-1516.

15. Plaza Perez I: Estado actual de los programas de prevención secundaria y rehabilitación cardíaca en España. Rev Esp Cardiol 2003; 56: 757-760.